Cogena, a novel tool for co-expressed gene-set enrichment analysis, applied to drug repositioning and drug mode of action discovery

BMC Genomics

Volumn 17, Issue 1, 2016, Pages

  Jia, Zhilong ^a,b   Liu, Ying ^c   Guan, Naiyang ^a,d   Bo, Xiaochen ^e   Luo, Zhigang ^a,d   Barnes, Michael R ^b  

^a NATIONAL UNIVERSITY OF DEFENSE TECHNOLOGY   (China)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c CENTRAL SOUTH UNIVERSITY   (China)

^d NATIONAL UNIVERSITY OF DEFENSE TECHNOLOGY   (China)

^e BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

Author keywords

Drug repositioning; Mode of action; Pathway analysis; Psoriasis

Indexed keywords

CYCLOSPORIN A; METHOTREXATE; TRANSCRIPTOME;

ARTICLE; CO EXPRESSED GENE SET ENRICHMENT ANALYSIS; COMPUTER PROGRAM; DRUG DEVELOPMENT; DRUG MECHANISM; DRUG REPOSITIONING; GENE EXPRESSION; GENETIC ANALYSIS; INTERMETHOD COMPARISON; ONLINE SYSTEM; PSORIASIS; TRANSCRIPTOMICS; ALGORITHM; CLUSTER ANALYSIS; GENE EXPRESSION PROFILING; GENE REGULATORY NETWORK; PROCEDURES; SOFTWARE; WEB BROWSER; WORKFLOW;

ALGORITHMS; CLUSTER ANALYSIS; DRUG DISCOVERY; DRUG REPOSITIONING; GENE EXPRESSION PROFILING; GENE REGULATORY NETWORKS; SOFTWARE; WEB BROWSER; WORKFLOW;

EID: 84973365118     PISSN: None     EISSN: 14712164     Source Type: Journal    
DOI: 10.1186/s12864-016-2737-8     Document Type: Article

References (60)

1. Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004;3(8):673-83.
2. Li YY, Jones SJ. Drug repositioning for personalized medicine. Genome medicine. 2012;4(3):27.
3. Duran-Frigola M, Aloy P. Recycling side-effects into clinical markers for drug repositioning. Genome medicine. 2012;4(1):3.
4. Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, Marshall KA, Phillippy KH, Sherman PM, Holko M, et al. NCBI GEO: archive for functional genomics data sets--update. Nucleic Acids Res. 2013;41(Database issue):D991-5.
5. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, Lerner J, Brunet JP, Subramanian A, Ross KN, et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science. 2006;313(5795):1929-35.
6. Liu C, Su J, Yang F, Wei K, Ma J, Zhou X. Compound signature detection on LINCS L1000 big data. Mol Biosyst. 2015;11(3):714-22.
7. Setoain J, Franch M, Martinez M, Tabas-Madrid D, Sorzano CO, Bakker A, Gonzalez-Couto E, Elvira J, Pascual-Montano A. NFFinder: an online bioinformatics tool for searching similar transcriptomics experiments in the context of drug repositioning. Nucleic Acids Res. 2015;43(W1):W193-9.
8. Cheng J, Yang L, Kumar V, Agarwal P. Systematic evaluation of connectivity map for disease indications. Genome medicine. 2014;6(12):540.
9. Li J, Zheng S, Chen B, Butte AJ, Swamidass SJ, Lu Z. A survey of current trends in computational drug repositioning. Brief Bioinform. 2015.
10. Oprea TI, Overington JP. Computational and Practical Aspects of Drug Repositioning. Assay Drug Dev Technol. 2015;13(6):299-306.
11. Nelson MR, Tipney H, Painter JL, Shen J, Nicoletti P, Shen Y, Floratos A, Sham PC, Li MJ, Wang J, et al. The support of human genetic evidence for approved drug indications. Nat Genet. 2015;47(8):856-60.
12. Niehrs C, Pollet N. Synexpression groups in eukaryotes. Nature. 1999;402(6761):483-7.
13. Stuart JM, Segal E, Koller D, Kim SK. A gene-coexpression network for global discovery of conserved genetic modules. Science. 2003;302(5643):249-55.
14. Gerstein MB, Rozowsky J, Yan KK, Wang D, Cheng C, Brown JB, Davis CA, Hillier L, Sisu C, Li JJ, et al. Comparative analysis of the transcriptome across distant species. Nature. 2014;512(7515):445-8.
15. Yang Y, Han L, Yuan Y, Li J, Hei N, Liang H. Gene co-expression network analysis reveals common system-level properties of prognostic genes across cancer types. Nat Commun. 2014;5:3231.
16. Bruneau P, Pinheiro P, Broeksema B, Otjacques B. Cluster sculptor, an interactive visual clustering system. Neurocomputing. 2014.
17. Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics. 2008;9:559.
18. Michalopoulos I, Pavlopoulos GA, Malatras A, Karelas A, Kostadima MA, Schneider R, Kossida S. Human gene correlation analysis (HGCA): a tool for the identification of transcriptionally co-expressed genes. BMC research notes. 2012;5:265.
19. Jupiter D, Chen HL, VanBuren V. STARNET 2: a web-based tool for accelerating discovery of gene regulatory networks using microarray co-expression data. Bmc Bioinformatics. 2009;10:332.
20. van Dam S, Cordeiro R, Craig T, van Dam J, Wood SH, de Magalhaes JP. GeneFriends: an online co-expression analysis tool to identify novel gene targets for aging and complex diseases. BMC Genomics. 2012;13:535.
21. CoExpress. http://www.bioinformatics.lu/CoExpress/. Accessed 20 Mar 2015.
22. Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44-57.
23. Chen EY, Tan CM, Kou Y, Duan Q, Wang Z, Meirelles GV, Clark NR, Ma'ayan A. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinformatics. 2013;14:128.
24. Pratanwanich N, Lio P. Pathway-based Bayesian inference of drug-disease interactions. Mol Biosyst. 2014;10(6):1538-48.
25. Pan Y, Cheng T, Wang Y, Bryant SH. Pathway analysis for drug repositioning based on public database mining. J Chem Inf Model. 2014;54(2):407-18.
26. Li Y, Li WG, Chen X, Jiang H, Sun JT, Chen H, et al. Integrated Analysis Identifies Interaction Patterns between Small Molecules and Pathways. Biomed Research International. 2014.
27. Ravindranath AC, Perualila-Tan N, Kasim A, Drakakis G, Liggi S, Brewerton SC, Mason D, Bodkin MJ, Evans DA, Bhagwat A, et al. Connecting gene expression data from connectivity map and in silico target predictions for small molecule mechanism-of-action analysis. Mol Biosyst. 2015;11(1):86-96.
28. Li J, Lu ZY. Pathway-based drug repositioning using causal inference. Bmc Bioinformatics. 2013;14 Suppl 16:S3.
29. Brock G, Datta S, Pihur V, Datta S. clValid: An R package for cluster validation. J Stat Softw. 2008;25(4):1-22.
30. Analytics R. doMC: Foreach parallel adaptor for the multicore package. R package version. 2013;1(0).
31. Lucas A. amap: Another Multidimensional Analysis Package. R package version 08-7. 2011.
32. Hardin J, Mitani A, Hicks L, VanKoten B. A robust measure of correlation between two genes on a microarray. Bmc Bioinformatics. 2007;8(1):1.
33. Liberzon A. A description of the Molecular Signatures Database (MSigDB) Web site. Methods Mol Biol. 2014;1150:153-60.
34. da Huang W, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 2009;37(1):1-13.
35. Nair RP, Duffin KC, Helms C, Ding J, Stuart PE, Goldgar D, Gudjonsson JE, Li Y, Tejasvi T, Feng BJ, et al. Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat Genet. 2009;41(2):199-204.
36. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 2003;4(2):249-64.
37. Wang X, Kang DD, Shen K, Song C, Lu S, Chang LC, Liao SG, Huo Z, Tang S, Ding Y, et al. An R package suite for microarray meta-analysis in quality control, differentially expressed gene analysis and pathway enrichment detection. Bioinformatics. 2012;28(19):2534-6.
38. Smyth GK. Limma: linear models for microarray data. In: Bioinformatics and computational biology solutions using R and Bioconductor. Springer; 2005. p. 397-420.
39. Szklarczyk D, Franceschini A, Wyder S, Forslund K, Heller D, Huerta-Cepas J, Simonovic M, Roth A, Santos A, Tsafou KP, et al. STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 2015;43(Database issue):D447-52.
40. Pradines JR, Farutin V, Rowley S, Dancik V. Analyzing protein lists with large networks: edge-count probabilities in random graphs with given expected degrees. J Comput Biol. 2005;12(2):113-28.
41. Phillips A. Psoriasis. Diagnosis and Management. Primary Health Care. 2015;25(6):13.
42. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545-50.
43. Gaffen SL, Jain R, Garg AV, Cua DJ. The IL-23-IL-17 immune axis: from mechanisms to therapeutic testing. Nat Rev Immunol. 2014;14(9):585-600.
44. Mabuchi T, Chang TW, Quinter S, Hwang ST. Chemokine receptors in the pathogenesis and therapy of psoriasis. J Dermatol Sci. 2012;65(1):4-11.
45. Baran W, Szepietowski JC, Szybejko-Machaj G. Expression of p53 protein in psoriasis. Acta Dermatovenerol Alp Pannonica Adriat. 2005;14(3):79-83.
46. Lima Ede A, Lima MM, Marques CD, Duarte AL, Pita Ida R, Pita MG. Peroxisome proliferator-activated receptor agonists (PPARs): a promising prospect in the treatment of psoriasis and psoriatic arthritis. An Bras Dermatol. 2013;88(6):1029-35.
47. Karvonen SL, Korkiamaki T, Yla-Outinen H, Nissinen M, Teerikangas H, Pummi K, Karvonen J, Peltonen J. Psoriasis and altered calcium metabolism: downregulated capacitative calcium influx and defective calcium-mediated cell signaling in cultured psoriatic keratinocytes. J Invest Dermatol. 2000;114(4):693-700.
48. National Psoriasis Fundation. www.psoriasis.org. Accessed May 2016.
49. Carter PH. Chemokine receptor antagonism as an approach to anti-inflammatory therapy: 'just right' or plain wrong? Curr Opin Chem Biol. 2002;6(4):510-25.
50. Rustin MH. Long-term safety of biologics in the treatment of moderate-to-severe plaque psoriasis: review of current data. Br J Dermatol. 2012;167 Suppl 3:3-11.
51. Leonardi C, Matheson R, Zachariae C, Cameron G, Li L, Edson-Heredia E, Braun D, Banerjee S. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med. 2012;366(13):1190-9.
52. Papp KA, Leonardi C, Menter A, Ortonne JP, Krueger JG, Kricorian G, Aras G, Li J, Russell CB, Thompson EH, et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med. 2012;366(13):1181-9.
53. Gordaliza M, Garcia PA, del Corral JM, Castro MA, Gomez-Zurita MA. Podophyllotoxin: distribution, sources, applications and new cytotoxic derivatives. Toxicon. 2004;44(4):441-59.
54. Wang Y, Xiao J, Suzek TO, Zhang J, Wang J, Bryant SH. PubChem: a public information system for analyzing bioactivities of small molecules. Nucleic Acids Res. 2009;37(Web Server issue):W623-33.
55. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, Davenport AP, McGrath JC, Peters JA, Southan C, et al. The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands. Nucleic Acids Res. 2014;42(Database issue):D1098-106.
56. Iorio F, Bosotti R, Scacheri E, Belcastro V, Mithbaokar P, Ferriero R, Murino L, Tagliaferri R, Brunetti-Pierri N, Isacchi A, et al. Discovery of drug mode of action and drug repositioning from transcriptional responses. Proc Natl Acad Sci U S A. 2010;107(33):14621-6.
57. Qu XA, Freudenberg JM, Sanseau P, Rajpal DK. Integrative clinical transcriptomics analyses for new therapeutic intervention strategies: a psoriasis case study. Drug Discov Today. 2014;19(9):1364-71.
58. Qing X, Jin W, Ju-Ying W, Hui-Lan Y, Ying-Quan L. Therapeutic effect of etoposide on experimental psoriasis. CJPT. 2008;22(6):440-5.
59. Gupta M, Mahajan VK, Mehta KS, Chauhan PS, Rawat R. Peroxisome proliferator-activated receptors (PPARs) and PPAR agonists: the 'future' in dermatology therapeutics? Arch Dermatol Res. 2015.
60. Khatri P, Sirota M, Butte AJ. Ten years of pathway analysis: current approaches and outstanding challenges. PLoS Comput Biol. 2012;8(2):e1002375.